Statins: Summary of Recommendations
- Full Report (1MB PDF)
- 2-Page summary (198k PDF)
- Easy-to-read: Statins Summary Report(496k PDF)
- Descargar El Resumen De 2 Páginas (120k PDF)
- Download Adobe Acrobat Reader
There are seven statins, but they're not all the same. Some deliver a greater reduction in cholesterol than others. In addition, some statins are backed by stronger evidence that they reduce the risk of a heart attack, death from heart disease, or stroke.
Statins can vary widely in cost as well—from as little as $11 per month to more than $200. Most people who take them must continue to do so for years—perhaps for the rest of their life—so the cost can be an important factor to consider.
Your individual circumstances, such as how much you need to lower your cholesterol and whether you have heart disease or have had a heart attack, should also be considered when looking at your options. Certain statins are better depending on your health status.
- Generic lovastatin or pravastatin—if you need to lower "bad" (LDL) cholesterol by less than 30 percent.
- Generic simvastatin (20 mg or 40 mg)—if you need an LDL reduction of 30 percent or more and/or have heart disease or diabetes, or if you've had a heart attack or have acute coronary syndrome and your LDL level is not highly elevated.
- Atorvastatin (Lipitor) (40 mg or 80 mg)—if you have had a heart attack or have acute coronary syndrome and your LDL is highly elevated.
Most people who need a statin should take the lowest dose that reduces their LDL cholesterol to an acceptable "target" level, because higher doses pose a greater risk of serious side effects, such as muscle, kidney, and liver problems. But some people—such as those who have had a heart attack—might need a higher dose.
No matter what dose you take, if you experience muscle aches and pains when taking a statin, contact your doctor immediately. Also, ask your doctor about splitting your statin pills. This can save you money and is a widely accepted practice.
Statins for High Cholesterol, Heart Disease: Drug Comparison
(1) "Generic" indicates drug sold by generic name.
(2) Prices reflect nationwide retail average for April 2010, rounded to nearest dollar; information derived by Consumer Reports Health Best Buy Drugs from data provided by Wolters Kluwer Pharma Solutions®. Wolters Kluwer is not involved in our analysis or recommendations.
(3) Nonfatal and fatal heart attack plus deaths attributed to heart disease.
(4) Lovastatin has not been proven to reduce deaths but the evidence strongly points in that direction.
(2) Prices reflect nationwide retail average for April 2010, rounded to nearest dollar; information derived by Consumer Reports Health Best Buy Drugs from data provided by Wolters Kluwer Pharma Solutions®. Wolters Kluwer is not involved in our analysis or recommendations.
(3) Nonfatal and fatal heart attack plus deaths attributed to heart disease.
(4) Lovastatin has not been proven to reduce deaths but the evidence strongly points in that direction.
(1) "Generic" indicates drug sold by generic name.
(2) Prices reflect nationwide retail average for April 2010, rounded to nearest dollar; information derived by Consumer Reports Health Best Buy Drugs from data provided by Wolters Kluwer Pharma Solutions®. Wolters Kluwer is not involved in our analysis or recommendations.
(3) Nonfatal and fatal heart attack plus deaths attributed to heart disease.
(4) Lovastatin has not been proven to reduce deaths but the evidence strongly points in that direction.
(5) Two studies cast doubt on the benefits of this drug. The first was a two-year study that found that Vytorin was no better than simvastatin alone in reducing plaque buildup in arteries. The second was a five-year study that found that Vytorin did not reduce strokes or heart attacks compared to placebo.
(2) Prices reflect nationwide retail average for April 2010, rounded to nearest dollar; information derived by Consumer Reports Health Best Buy Drugs from data provided by Wolters Kluwer Pharma Solutions®. Wolters Kluwer is not involved in our analysis or recommendations.
(3) Nonfatal and fatal heart attack plus deaths attributed to heart disease.
(4) Lovastatin has not been proven to reduce deaths but the evidence strongly points in that direction.
(5) Two studies cast doubt on the benefits of this drug. The first was a two-year study that found that Vytorin was no better than simvastatin alone in reducing plaque buildup in arteries. The second was a five-year study that found that Vytorin did not reduce strokes or heart attacks compared to placebo.
- Full Report (1MB PDF)
- 2-Page summary (198k PDF)
- Easy-to-read: Statins Summary Report(496k PDF)











